Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coagulation monitor maker HemoSense prices IPO at $19.25m:

This article was originally published in Clinica

Executive Summary

HemoSense, the San Jose, California-based maker of the INRatio point-of-care device for patients taking oral anticoagulants to monitor the clotting time of their blood, has priced its initial public offering. It plans to offer 3.5 million shares at $5.50 each, for proceeds of $19.25m. Underwriters also have an option to purchase an additional 525,000 shares to cover over-allotments. The stock will be listed on the American Stock Exchange.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT055645

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel